MedTrace Logo

Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients

NCT03146247 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-04-18

No results posted yet for this study

Summary

This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast. This data will be complemented by immunohistochemical data determining nerve ending density and neuropeptide concentrations before and during treatment and correlated with patient reported outcome. It is important to underscore that itch may interfere with various aspects of patient functioning, emotions and social status and should therefore be adequately addressed while treating patients with psoriasis

Conditions

Interventions

DRUG

Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet

All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.

Sponsors & Collaborators

  • Diamant Thaci

    lead OTHER

Principal Investigators

  • Diamant Thaci, Prof. · Universität zu Lübeck

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-23
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03146247 on ClinicalTrials.gov